

Androgen-regulated gastrin-releasing peptide receptor expression in androgen-dependent human prostate tumor xenografts

Rogier P.J. Schroeder^{1,2}, Monique de Visser¹, Wytske M. van Weerden², Corrina M.A. de Ridder², Suzanne Reneman², Marleen Melis¹, Wout A.P. Breeman¹, Eric P. Krenning¹ and Marion de Jong¹

¹Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands

²Experimental Urology, Erasmus MC, Rotterdam, The Netherlands

Human prostate cancer (PC) overexpresses the gastrin-releasing peptide receptor (GRPR). Radiolabeled GRPR-targeting analogs of bombesin (BN) have successfully been introduced as potential tracers for visualization and treatment of GRPR-overexpressing tumors. A previous study showed GRPR-mediated binding of radiolabeled BN analogs in androgen-dependent but not in androgen-independent xenografts representing the more advanced stages of PC. We have further investigated the effect of androgen modulation on GRPR-expression in three androgen-dependent human PC-bearing xenografts: PC295, PC310 and PC82 using the androgen-independent PC3-model as a reference. Effects of androgen regulation on GRPR expression were initially studied on tumors obtained from our biorepository of xenograft tissues performing reverse transcriptase polymerase chain reaction (RT-PCR) and autoradiography (¹²⁵I-universal-BN). A prospective biodistribution study (¹¹¹In-MP2653) and subsequent autoradiography (¹²⁵I-GRP and ¹¹¹In-MP2248) was then performed in castrated and testosterone resupplemented tumor-bearing mice. For all androgen-dependent xenografts, tumor uptake and binding decreased drastically after 7 days of castration. Resupplementation of testosterone to castrated animals restored GRPR expression extensively. Similar findings were concluded from the initial autoradiography and RT-PCR studies. Results from RT-PCR, for which human specific primers are used, indicate that variations in GRPR expression can be ascribed to mRNA downregulation and not to castration-induced reduction in the epithelial fraction of the xenograft tumor tissue. In conclusion, expression of human GRPR in androgen-dependent PC xenografts is reduced by androgen ablation and is reversed by restoring the hormonal status of the animals. This knowledge suggests that hormonal therapy may affect GRPR expression in PC tissue making GRPR-based imaging and therapy especially suitable for non-hormonally treated PC patients.

Prostate cancer (PC) is the third leading cause of cancer-related deaths and the most frequently diagnosed cancer in men in Western countries.¹ PC will increase to be a major health problem due to the aging of people in the Western world and currently developed screening strategies that result in diagnosis at more early stage of disease. In case of metastasized late stage PC, standard therapy exists of hormone deprivation, which is initially effective in the majority of patients.² Eventually, however, patients with PC will relapse due to progression of PC towards hormone-independent growth of the tumor. Unfortunately, advanced PC responds

poorly to chemotherapeutic agents of which taxane-based treatments are nowadays considered the standard second-line treatment of hormone-resistant PC.^{3,4} Finally, most patients with metastasized PC will die of progressive, hormone-independent disease. Treatment and imaging of PC demands for new concepts, a potential strategy lies in targeting tumor-specific receptors. It could improve staging of PC determining locality of disease at time of diagnosis which is required to define treatment decisions.

It has been shown that prostate tumors overexpress the gastrin-releasing peptide receptor (GRPR).⁵⁻⁹ Overexpression of these receptors in PC is restricted to the malignant cells, as normal and hyperplastic prostate tissue were shown to be GRPR-negative.⁵ The GRPR is a member of the bombesin (BN) receptor family consisting of 4 known receptor subtypes. Three of them, the neuromedin B (NMB) receptor (BB₁), GRPR (BB₂) and BN receptor subtype 3 (BRS-3 or BB₃), are mammalian receptors, whereas the fourth subtype (BB₄) is found only in amphibians.⁹⁻¹³ BN-like receptors, such as NMB, BB₂ and BB₃ are involved in the regulation of a large number of biological processes in the gut and central nervous system¹⁴ and mediate their action by binding to their BN receptor subtypes. BN analogs are attractive peptides to be used

Key words: androgen-regulation, biodistribution, bombesin, gastrin-releasing peptide receptor, prostatic neoplasms, xenografts

The first two authors contributed equally to this work

Grant sponsor: Dutch Cancer Society; **Grant number:** 12977368

DOI: 10.1002/ijc.25000

History: Received 6 Mar 2009; Accepted 18 Aug 2009; Online 28 Oct 2009

Correspondence to: Rogier P.J. Schroeder, Erasmus MC Rotterdam, Room Be331 (JN1), Dr. Molenwaterplein 50, GE Rotterdam 3015, The Netherlands, Tel: +31107043381, Fax: +31107044661, E-mail: r.schroeder@erasmusmc.nl

to target the GRPR. Its use has been proposed for chemotherapy using cytotoxic BN analogs and for nuclear interventions employing radiolabeled BN analogs to perform peptide-receptor scintigraphy and radionuclide therapy (PRRT).⁵

In a previous study, we evaluated the expression of GRPRs in different stages of tumor development using a panel of 12 xenograft models from 9 different patients representing the various stages of human PC ranging from androgen-dependent to androgen-independent disease.^{15,16} We found GRPR-mediated binding of radiolabeled BN analogs only in androgen-dependent but not in androgen-independent xenografts representing the more advanced stages of prostate tumor development.¹⁷ Also, in a pilot study, GRPR-expression of an androgen-dependent xenograft showed reduced uptake after androgen ablation treatment, suggesting that GRPR-expression may be influenced by androgens and may be related to the progressive state of PC.

As the majority of patients are treated with hormonal therapy during the course of their disease, it is highly relevant to study the impact of hormonal ablation treatment on GRPR expression to reveal whether such patients could still be eligible to GRPR targeted modalities. Therefore, the purpose of this study was to further investigate androgen regulation of the GRPR in 3 androgen-dependent human PC xenograft models PC82, PC295 and PC310 that represent the early androgen-responsive state of human PC.¹⁸ We hypothesized that if GRPR is androgen regulated, the expression is reduced by androgen ablation in androgen-dependent xenograft-bearing mice and should be reversed by restoring the hormonal status of the animals. This experimental design allows to elucidate the direct effects of hormonal changes on GRPR expression in relevant models for human PC. Because resupplementation of patients with testosterone is not likely to be applicable in patients with PC, this study setup is merely experimental in nature and less intended to mimic the clinical setting. Knowledge about the background of hormonal regulation of the GRPR will provide crucial information for the clinical use of GRPR-based technologies. It enables to define patient groups that may benefit from GRPR targeted modalities. As a reference, the androgen-independent xenograft model PC3 was used. Although PC3 is androgen-independent, GRPR is constitutively overexpressed and, therefore, this model is frequently used in studies on GRPR expression in PC.

Materials and Methods

PC xenografts

For this study, we made use of intact male nude NMRI (Naval Medical Research Institute) mice (Taconic M&B, RY, Denmark).^{15–17} The experiment was approved by the Dutch National Animal Experimental Committee and performed in agreement with The Netherlands Experiments on Animals Act (1977) and the European Convention for protection of Vertebrate Animals used for Experimental Purposes (Strasbourg, March 18, 1986).

Mice were implanted subcutaneously with small fragments of the androgen-dependent PC82, PC295 and PC310 human prostate tumor.¹⁵ Mice were supplemented with testosterone to obtain optimal tumor take (80–85%) and tumor growth by implanting silastic tubings filled with crystalline steroid (6 mg/tubing; AppliChem, Darmstadt, Germany). These implants result in constant delivery of testosterone exceeding the low physiological levels in intact male nude mice for at least 75 days.¹⁹ For the androgen-independent PC3 xenografts, cell suspensions (5 million cells per mouse) were injected subcutaneously without additional testosterone supplementation.

Androgen ablation and testosterone resupplementation

Androgen withdrawal was performed by surgical castration under Ketamin (Alfasan, Woerden, The Netherlands) and Rompun (Bayer AG, Leverkusen, Germany) anesthesia (mix of 1:1), and subsequent removal of testosterone implants. At 2, 4 and 7 days after castration, mice were used for biodistribution studies. Control mice were used when tumor volumes were between 600 and 800 mm,³ which was reached approximately 90 days after tumor implantation. Castration of tumor-bearing mice was planned in such a way that tumor volumes at time of inclusion were in the same range as those of the control mice.

Resupplementation of testosterone to mice was accomplished under Ketamin:Rompun anesthesia by subcutaneous reimplantation of testosterone implants at 7 days after castration. Biodistribution was then performed at a predefined number of days after resupplementation (2, 4 or 14 days).

Radiolabeled peptides

BN analogue [D-Tyr⁶, β-Ala¹¹, Phe¹³, Nle¹⁴]BN(6-14) referred to as universal-BN was provided by Biosynthema (St. Louis, MO) and radiolabeled with ¹²⁵I as described previously (radiolabeled compound as from now referred to as ¹²⁵I-universal-BN).²⁰ ¹²⁵I-labeled GRP was obtained commercially from Amersham Biosciences (Buckinghamshire, United Kingdom).

BN analogs (MP2248) and (MP2653) were provided by Mallinckrodt (St. Louis, MO) and radiolabeled with ¹¹¹In (¹¹¹InCl₃, Tyco Healthcare, Petten, the Netherlands, DRN 4901, 370 MBq/ml in HCl, pH 1.5–1.9) as described earlier.^{21–24}

RNA isolation and quantitative reverse transcriptase polymerase chain reaction

For reverse transcriptase polymerase chain reaction (RT-PCR), an independent set of PC82, PC295 and PC310 tumor tissue was obtained from our biorepository of xenograft tissues (snapfrozen material stored at minus 80°C) and not from tissues from the biodistribution studies as snapfrozen tissues are essential to obtain high-quality RNA. Tumors from the biodistribution studies could only be frozen after

counting in the gammacounter, in which time delay strongly affects the RNA quality.

Total RNA was isolated using RNazol B kit (Bio-connect, Huissen, The Netherlands) according to the manufacturer's protocol. The reverse transcriptase reaction was performed with 1 µg of RNA and 100 ng/µl of oligo(dT)₁₂₋₁₈ primer (Invitrogen, Carlsbad, CA) for 10 min at 70°C in 11 µl volume and chilled on ice. cDNA was reverse transcribed in first-strand buffer (4 µl, 5×; Invitrogen) plus 2 µl of 100 mM DTT, 1 µl of 10 mM dNTP mix, 1 µl of RNasin ribonuclease inhibitor (Invitrogen) and 200 U of MMLV-RT (Invitrogen) followed by 1 hr incubation at 37°C. The process was inactivated by heating to 95°C for 10 min, and the samples were then stored at -20°C.

Gene expression of GRPR and the housekeeping gene glyceraldehydes-3-phosphate dehydrogenase (GAPDH) was performed with human-specific primers and probes purchased as a FAM dye-labeled TaqMan MGB primer probe kit (Applied Biosystems, Foster City, USA). GAPDH was used as the endogenous reference gene to relate GRPR mRNA levels to the total epithelial (human) cell content of each sample. The real-time PCR reaction was performed in a volume of 25 µl containing cDNA. PCR mixture contained a final concentration of 360 nM primer, 100 nM probe, commercially available PCR mastermix (TaqMan Universal PCR Mastermix; Applied Biosystems). The PCR mastermix contained 10 mM of Tris-HCl (pH 8.3), 50 mM of KCl, 5 mM of MgCl₂, 2.5 mM of deoxynucleotide triphosphates, 0.625 U of AmpliTaq Gold DNA polymerase and 0.25 U AmpErase UNG per reaction. Samples were amplified in an automated fluorometer (ABI Prism 7700 Sequence Detection System; Applied Biosystems). Amplification conditions were 2 min at 50°C, 10 min at 95°C, 40 cycles of 15 sec at 95°C and 60 sec at 60°C. The amount of target gene expressed was related to a calibrator composed of a mixture of cDNAs from different PC xenografts. Results were calculated for each cell line as the average relative quantity of the 2 tissue samples analyzed in duplicate.

Statistical analysis was performed using the unpaired 2-tailed *t*-test using SPSS 15.0 (SPSS Inc., Chicago, IL). A probability of less than 0.05 was considered significant.

Biodistribution studies

For biodistribution studies, mice were injected intravenously with 4 MBq/60 pmol (0.1 µg)/200 µl of the radiolabeled BN analog ¹¹¹In-MP2653 at predefined time points, and sacrificed 4 hr after peptide injection. Tumor tissue and the GRPR-positive pancreas as well as kidneys and intestines (relevant organs for clearing) were collected for counting of radioactivity in a LKB-1282-compugamma system (Perkin Elmer, Oosterhout, the Netherlands). Radioactive uptake was calculated as % injected dose per gram of tissue (%ID/g) as a percentage of the control group (100%). Immediately after counting, the tumors were snapfrozen in liquid nitrogen for autoradiography.

Statistical analysis was performed using the Mann-Whitney and unpaired *t*-test. A probability of less than 0.05 was considered significant.

Autoradiographic analyses

PC xenograft tumor tissues derived from hormonally manipulated mice were evaluated for GRPR expression by *in-vitro* autoradiography as described previously.¹⁷ In short, frozen xenograft sections (10 µm) were incubated for 1 hr at room temperature with 0.1 nM radiolabeled compound. To discriminate between GRPR-mediated binding and nonreceptor-mediated binding, sections were incubated in the presence of an excess (1 µM) of unlabeled GRP or [Tyr⁴]BN (Sigma Aldrich, Zwijndrecht, The Netherlands) as a blocking agent. Sections were exposed to phosphor imaging screens (Perkin Elmer, Boston, MA) for 16–72 hr. Screens were read using a Cyclone Storage Phosphor System (Packard, Meriden, USA), and autoradiograms were quantified using Optiquant Software (Packard, Meriden, USA). Results are indicated as average GRPR-mediated radiolabeled peptide binding (net Density Light Units/mm² of total binding minus nonspecific binding) as a percentage of the control group (100%).

Statistical analysis was performed using the Mann-Whitney and unpaired *t*-test. A probability of less than 0.05 was considered significant.

Results

Effect of androgens on GRPR mRNA levels:

Quantitative RT-PCR

To evaluate changes in mRNA expression of GRPR during androgen manipulation, RT-PCR was performed on RNA from an independent set of PC82, PC295 and PC310 tumor tissue obtained from our biorepository of xenograft tissues. To correct for variability of stromal (murine) content of the otherwise human (epithelial) tumors, human-specific probes were used, and GRPR mRNA levels were related to GAPDH. Relative GRPR mRNA levels under control conditions were high for PC295 and PC310 with a mean GRPR/GAPDH ratio of 27.2 and 21.5, respectively. PC82 showed much lower GRPR mRNA levels with a mean GRPR/GAPDH ratio of 4.1. After androgen ablation, the relative GRPR expression dropped considerably for PC295, PC310 and PC82 (Fig. 1). Resupplementation with testosterone resulted in recovery of GRPR mRNA levels for all xenografts, although recovery levels were quite variable (Fig. 1).

Effect of androgens on GRPR-mediated tumor uptake:

Biodistribution studies

Subsequent to the RT-PCR and initial autoradiography, a prospective biodistribution study was performed to evaluate potential androgen regulation of GRPR, and thus the effect of androgen status on GRPR-mediated tumor uptake *in vivo* using the radiolabeled BN analog ¹¹¹In-MP2653 in PC tumor-bearing mice under hormonal manipulation. Table 1 summarizes the results of 3 independent biodistribution




Figure 1. Results of RT-PCR performed in androgen-dependent PC bearing mice; PC295 (a), PC82 (b) and PC310 (c). Tumor tissue was obtained from control mice, castrated mice (castration 9–22 days before tumor collection) or castrated mice that were testosterone resupplemented (castration 12–22 days before testosterone resupplementation of 7–45 days). Each tissue sample was performed in duplicate. Results are shown as an average of the 2 GRPR/GAPDH measurements (mean \pm SD). *Statistically significant difference compared to the mean of the control group ($p < 0.05$).

studies. The first experiment was performed with the androgen dependent PC295 xenograft. The outcome of this study was further substantiated in a subsequent biodistribution

study using the androgen sensitive xenograft PC82 with a more extended time point of testosterone re-supplementation. Finally, to validate the outcome of these 2 experiments, a third biodistribution study was performed with the androgen sensitive xenograft models PC295, PC82 and PC310, comparing GRPR expression in intact mice (control), castrated mice (cas 7) and castrated and resupplemented mice (cas 7 T 14) with the androgen-independent PC3 as reference model.

The uptake of the ^{111}In -labeled peptide at 4 hr after injection in the GRPR-positive tumor and GRPR-expressing pancreas as well as in the clearance organs (kidneys and intestines) were found to be in agreement with our previous results obtained with ^{111}In -MP2653 in mice bearing PC3 tumors.²⁵ Tumor and pancreas uptake in all PC xenografts are summarized in Table 1. The androgen-dependent PC tumors demonstrated a significant inhibition of growth after androgen ablation (data not shown). The androgen-dependent xenografts also show a reduction in tumor uptake of ^{111}In -MP2653 after 4 and 7 days of castration. This decline was strongest in PC295 showing a decrease in tumor uptake of 73% ($p = 0.0002$) after 7 days of castration. The reduction of peptide uptake in androgen depleted PC82 and PC310 tumors was less pronounced than in PC295, although still significant (54% and 41%, respectively, after 7 days of castration, $p < 0.017$).

Resupplementation of testosterone to castrated mice for 14 days resulted in near complete recovery of tumor uptake in PC82 and PC310 mice to control levels (86% and 99%, respectively). For PC295, a partial restoration (40%) of peptide uptake by the tumors was observed after 4 days of testosterone resupplementation.

Tumor growth of the androgen-independent PC3 model was not affected by ablation treatment nor by testosterone supplementation (data not shown). In contrast to the androgen sensitive xenografts, tumor uptake of ^{111}In -MP2653 was significantly increased up to 141% at 7 days postcastration, which was normalized after testosterone resupplementation.

^{111}In -MP2653 uptake in the GRPR expressing pancreas was similar for all mice under the various hormonal conditions (Table 1).

Effect of androgens on GRPR-mediated binding:

Autoradiographic analyses

The effect of androgen status on GRPR-mediated binding in human PC was evaluated *in vitro* by autoradiography. Initially, autoradiographic analysis was performed on tumor sections derived from our biorepository of xenograft tissues (snapfrozen material stored at -80°C) using ^{125}I -universal-BN (74 TBq/mmol). This tumor collection contained tissues from control mice, castrated mice (castrated 8–10 days prior to sacrifice) and castrated mice that were resupplemented with testosterone for indicated days (Fig. 2). Binding of ^{125}I -universal-BN was drastically reduced after androgen ablation in all 3 androgen-dependent PC xenografts resulting in 95, 77 and 90% reduced binding in PC295, PC310 and PC82,

Table 1. Results of biodistribution and *in-vitro* autoradiographic studies

Group	Study	PC295		PC82		PC310		PC3		Pancreas ¹	
		% Control	(n)	% Control	(n)	% Control	(n)	% Control	(n)	% Control	(n)
Control	Uptake ¹¹¹ In-MP2653 ²	100 ± 31	(11)	100 ± 31	(14)	100 ± 19	(4)	100 ± 33	(12)	100 ± 21	42
	Binding ¹²⁵ I-GRP ³	100 ± 19		100 ± 37		100 ± 67		100 ± 53			
	Binding ¹¹¹ In-MP2248 ⁴	100 ± 36		100 ± 54		100 ± 25		100 ± 42			
cas 2	Uptake ¹¹¹ In-MP2653 ²	124 ± 29	(5)	109 ± 37	(3)	nd		nd		nd	
	Binding ¹²⁵ I-GRP ³	72 ± 6.9 ⁵		67 ± 26							
	Binding ¹¹¹ In-MP2248 ⁴	55 ± 17 ⁵		67 ± 28							
cas 4	Uptake ¹¹¹ In-MP2653 ²	22 ± 7.3 ⁵	(5)	56 ± 30	(3)	nd		nd		nd	
	Binding ¹²⁵ I-GRP ³	11 ± 8.1 ⁵		29 ± 27 ⁵							
	Binding ¹¹¹ In-MP2248 ⁴	6.5 ± 6.4 ⁵		27 ± 30							
cas 7	Uptake ¹¹¹ In-MP2653 ²	27 ± 22 ⁵	(12)	46 ± 17 ⁵	(8)	59 ± 4.0 ⁵	(5)	141 ± 24 ⁵	(5)	101 ± 32	33
	Binding ¹²⁵ I-GRP ³	3.4 ± 1.9 ⁵		12 ± 5.3 ⁵		55 ± 14		123 ± 54			
	Binding ¹¹¹ In-MP2248 ⁴	1.5 ± 0.8 ⁵		7.7 ± 3.8 ⁵		52 ± 28		120 ± 19			
cas 7 T 2	Uptake ¹¹¹ In-MP2653 ²	35.8 ± 11	(5)	62 ± 10	(3)	nd		nd		nd	
	Binding ¹²⁵ I-GRP ³	20 ± 6.0 ⁶		33 ± 4.6 ⁶							
	Binding ¹¹¹ In-MP2248 ⁴	14 ± 6.5 ⁶		28 ± 6.4 ⁶							
cas 7 T 4	Uptake ¹¹¹ In-MP2653 ²	40 ± 9.4	(4)	107 ± 12 ⁶	(3)	nd		nd		nd	
	Binding ¹²⁵ I-GRP ³	30 ± 9.7 ⁶		60 ± 23 ⁶							
	Binding ¹¹¹ In-MP2248 ⁴	17 ± 6.3 ⁶		56 ± 10 ⁶							
cas 7 T 14	Uptake ¹¹¹ In-MP2653 ²	nd		86 ± 46	(8)	99 ± 30 ⁶	(5)	95 ± 47	(5)	99 ± 17	20
	Binding ¹²⁵ I-GRP ³			91 ± 30 ⁶		50 ± 19		112 ± 76			
	Binding ¹¹¹ In-MP2248 ⁴			87 ± 40 ⁶		83 ± 21		125 ± 49			

¹Groups consist of pancreas from non tumour-bearing and tumour bearing androgen supplemented, castrated and castrated subsequently resupplemented intact mice. ²Biodistribution results are average tumour and pancreas uptake of ¹¹¹In-MP2653 (% injected dose/gram tissue) as percentage of controls (100%) per hormonally manipulated group; data are expressed as mean ± SD. Numbers of animals used per group are stated under (n). ^{3,4}*In-vitro* autoradiography results are average GRPR-mediated binding (net DLU/mm² of total binding – nonspecific binding) as percentage of controls (100%) of ¹²⁵I-GRP and ¹¹¹In-MP2248 data are expressed as mean ± SD. Numbers of animals used per group are stated under (n). ⁵Significantly different from control group ($p < 0.05$). ⁶Significantly different from castration for 7 days group ($p < 0.05$). Abbreviations: cas, castration (for 2, 4 or 7 days); T, testosterone resupplementation (for 2, 4, or 14 days); nd, not determined.

respectively. Testosterone resupplementation partially restored binding to 70 and 54% of control level as observed for PC295 and PC82, respectively, while such restoration of peptide binding was not observed for PC310 after 13 days of testosterone administration (Fig. 2).

Additional autoradiographic evaluations were performed on tumor sections derived from the prospective biodistribution studies using ¹²⁵I-GRP (74 TBq/mmol) or ¹¹¹In-MP2248 (200 MBq/nmol) as ligands. In compliance with the biodistribution results, PC295 and PC82 showed strong and significant responses to androgen ablation. After 7 days of castration GRPR-binding was reduced by more than 96% ($p < 0.0001$) and 88% ($p = 0.0003$) for PC295 and PC82, respectively (Figs. 3a and 3b). A partial, though significant recovery of GRPR-binding was observed for PC295 and PC82 (17%: $p = 0.004$ and 56%: $p = 0.0002$, respectively) at 4 days of testosterone resupplementation with near-complete restoration of receptor-binding at 14 days of testosterone resupplementation for PC82 (to 91%). For PC310, the reduc-

tion in peptide binding after castration as was less pronounced (45%) and recovery after testosterone resupplementation was only moderate (Fig. 3c). Consistent with the biodistribution data, the androgen-independent PC3 model demonstrated a rise in GRPR-binding after testosterone ablation, which was restored to control levels after testosterone resupplementation (Fig. 3d).

Autoradiograms of PC82 tumor sections incubated with 10^{-10} M ¹¹¹In-MP2248 with or without blocking agent Tyr⁴-BN (10^{-6} M) revealed a heterogeneous distribution pattern of the BN-tracer within these samples (Fig. 4).

Discussion

Opportunistic screening for PC has led to diagnosis of more PC tumors still confined to the prostate in which curative surgical intervention is still an option. However, because of lack of accurate imaging modalities for PC, the (micro)metastatic stage of the tumor is often difficult to determine. The metastatic stage of PC greatly influences prognosis and




Figure 2. GRPR-specific binding of ^{125}I -universal-BN (= total binding ^{125}I -universal-BN 10^{-10} M) minus nonspecific binding (^{125}I -universal-BN 10^{-10} M + GRP 10^{-6} M) to androgen-dependent PC xenograft sections. Tumor tissue was obtained from control mice, castrated mice (castration 7–10 days before tumor collection) or castrated mice that were testosterone resupplemented (castration + testosterone = 57 + 38 days, 29 + 13 days and 20 + 22 days for PC295, PC310 and PC82, respectively). Results are shown as average net Density Light Units per mm^2 (net DLU/ mm^2). Results are average from 3 independent samples (except for the castration + testosterone group of which we had 1 sample) \pm SD. We used 2–4 sections per independent sample.

determines therapeutic options of the disease. Therefore, reliable and sensitive diagnostic tools are highly wanted to improve staging at time of diagnosis. Radiolabeled BN analogs may be promising new radiopharmaceuticals for imaging and therapy for patients with GRPR-expressing tumors, such as PC.^{26–31}

Evaluation of GRPR expression throughout the different stages of human prostate tumor development using a panel of 12 well-established human PC xenograft models has shown that GRPRs were predominantly expressed in androgen-dependent xenografts and were very low in androgen-independent xenografts.¹⁷ This observation stimulated further research into the potential effects of androgen status on the expression of the GRPR in patients with PC and, consequently, the relevance of their clinical history (therapy sequence). To further study androgen regulation of the GRPR, we used three androgen-responsive PC models. We hypothesized that if GRPR-expression was indeed regulated by androgens, androgen ablation of androgen-dependent xenograft bearing mice would reduce GRPR expression and recovery of androgen status would induce reappearance of GRPR expression. An initial *in-vitro* autoradiographic binding study using ^{125}I -universal-BN as ligand supported our hypothesis. Complete inhibition of GRPR binding was observed after androgen withdrawal for all xenografts, which could be recovered after supplementation with testosterone for PC295 and PC82. The reason for the lack of recovery of GRPR binding in the PC310 tumor is not completely clear. It might be related to the shorter resupplementation period indicating that restoration of GRPR mRNA expression is a relatively slow process (Fig. 2).




Figure 3. Receptor-mediated binding of ^{111}In -MP2248 to androgen-dependent PC295 (a), PC82 (b), PC310 (c) and androgen-independent PC3 (d) xenograft sections. Tumor tissue was derived from the tumor-bearing mice from the biodistribution study. Autoradiography results are average receptor-mediated binding (net DLU/ mm^2 of total binding – nonspecific binding) as percentage of the control group (100%) \pm SEM. $N = 4$ –14 xenografts/group, 2 sections per xenograft tumor were used. cas, castration for 2, 4 or 7 days; T, testosterone resupplementation for 2, 4 or 14 days; *significantly different from control group ($p < 0.05$); **significantly different from cas 7 group ($p < 0.05$).

RT-PCR study showed that after ablation of androgens, GRPR mRNA expression was significantly reduced in all androgen-dependent tumor types, while restoration of relative GRPR mRNA levels was achieved after androgen resupplementation. Variability in recovery of GRPR may be related to differences in the kinetics of the process of GRPR translation from mRNA to protein and reappearance. These results supported our hypothesis that in androgen-dependent xenografts representing early stage of PC, transcription of GRPR mRNA is androgen regulated.

Subsequent *in-vivo* biodistribution studies were performed with the previously evaluated ^{111}In -MP2653 analog.²⁵ Consistent with the autoradiographic results, ^{111}In -MP2653 tumor uptake was significantly reduced in all three androgen-dependent xenografts upon castration of tumor-bearing mice, which could be largely restored by resupplementation with testosterone. GRPR-expression of the androgen independent PC3 model was not downregulated by androgen withdrawal. Likewise, uptake of peptide by the GRPR expressing pancreas




Figure 4. *In-vitro* autoradiograms of PC82 tumor sections incubated with 10^{-10} M ^{111}In -MP2248 with or without an additional blocking agent Tyr⁴-BN (10^{-6} M). Xenografts were derived from castrated and testosterone resupplemented mice used in the biodistribution.

was not affected indicating that GRPR expression in the pancreas was not androgen regulated. These observations were further substantiated by additional *in-vitro* autoradiographies showing a similar trend in which castration induced reduction of GRPR binding and testosterone resupplementation induced restoration of GRPR expression in all 3 models of androgen-regulated human PC. Although results between biodistribution and autoradiography did show the same trend the changes in GRPR expression were larger in autoradiography studies. This may be explained by the more complex physiology of the *in-vivo* biodistribution process that involves interfering aspects such as *in-vivo* stability of the peptide (affecting retention of the peptide/label), tumor vascularisation (influencing uptake) and clearance of the peptide from the blood.^{32–34}

We wanted to define to which BN receptor(s) variations in binding of ^{125}I -universal-BN were related and especially if they were exclusively GRPR-related. Therefore, we examined if binding of ^{125}I -universal-BN to the androgen-dependent PC295, PC310 and PC82 tumor tissues could be blocked by 10^{-6} M of unlabeled GRP which was indeed the case (data not shown). Results are consistent with our previous findings.¹⁷ Because ^{125}I -universal-BN binding showed to be exclusively GRPR-related, the natural GRPR ligand, ^{125}I -GRP, was employed for a subsequent autoradiography study.

GRP is, however, a larger peptide than BN, and therefore it is more vulnerable to enzymatic degradation, making it is not a very suitable peptide for *in-vivo* experiments. For this reason, the shorter and more stable BN analog ^{111}In -MP2248 was also used. Similarities between the autoradiographies of both peptides confirmed that the BN analog ^{111}In -MP2248 indeed targets the GRPR like the natural GRP peptide. The relatively small variations in absolute values can be explained by the small differences in GRPR affinities of GRP and MP2248. This study showed that peptide uptakes by the tumors are comparable. These data indicate that for future studies only one peptide, preferably a BN-analog, may be chosen as the preferred ligand because this ligand can be employed for both *in vitro* and *in vivo* studies.

PC3 is a GRPR expressing androgen-independent model of human PC that is extensively used in literature. It has no androgen receptor and lacks the ability to produce PSA. Although GRPR is constitutively active in PC3 and the model is not suitable for studying androgen regulation of GRPR, its use in the field of BN-targeted imaging of PC obliged its use as reference model in this study. Our results confirm that GRPR expression in PC3 xenografts is not downregulated by castration and upregulated by resupplementation of androgens.

Xenograft tumor tissue consists of human epithelial tumor cells and supportive stromal cells originating from the mouse. Androgen-dependent PC xenografts will have regression of epithelial tumor fraction upon androgen ablation. Consequently, tumors in such xenografts will contain less (human) epithelial cells as compared to the (nonandrogen responsive) stromal compartment. It was essential to verify whether the observed effects were caused by regulation of GRPR expression itself or by changes in the total epithelial (human) content of the xenograft. RT-PCR enables to correct for these changes, while expression of GRPR mRNA was related to GAPDH mRNA expression levels using human-specific primer probe sets for both GRPR and GAPDH hereby excluding the non human stromal compartment.

Although none of our xenograft models representing late stage disease expressed GRPR,³⁵ it cannot be excluded that GRPR may be reexpressed in progressive, late stage disease as has been suggested from patient samples⁵ and few patients in clinical studies.³¹

Conclusion

GRPR-binding of androgen-dependent human PC xenograft models is androgen-regulated. Androgen ablation results in downregulation of GRPR expression. This expression can be (partially) restored by subsequent resupplementation with testosterone. Data further showed that the decline in GRPR-binding is the result of GRPR mRNA downregulation rather than the consequence of the castration-induced reduction in the epithelial fraction of the xenograft. This suggests that

hormonal therapy may affect GRPR expression in early stage, hormonally treated patients with PC. Our observations do not exclude, however, that GRPR expression may reappear in progressive late stage patients.

Our data indicate that GRPR is a promising target for imaging of early PC in patients who have not been treated by hormonal therapy. GRPR-based imaging modalities may thus be used to improve staging of hormone naïve patients with PC. Its potential as a therapeutic modality for PC may

be limited to nonhormonally treated patients, although reports suggest that GRPR may be reexpressed at later stages of PC. Studies are underway to further validate and compare GRPR expression in tumor tissue derived from both hormonally treated and untreated patients at different stages of PC.

Acknowledgements

We thank Erik de Blois (MSc) for radiolabeling of the BN peptides, and Ms. Nanda Wildeman for her help with the autoradiographic experiments.

References

- Jemal A, Thun MJ, Ries LA, Howe HL, Weir HK, Center MM, Ward E, Wu XC, Ehemann C, Anderson R, Ajani UA, Kohler B, et al. Annual report to the nation on the status of cancer, 1975–2005, featuring trends in lung cancer, tobacco use, and tobacco control. *J Natl Cancer Inst* 2008; 100:1672–94.
- Scherr D, Swindle PW, Scardino PT. National Comprehensive Cancer Network guidelines for the management of prostate cancer. *Urology* 2003;61:14–24.
- Mancuso A, Oudard S, Sternberg CN. Effective chemotherapy for hormone-refractory prostate cancer (HRPC): present status and perspectives with taxane-based treatments. *Crit Rev Oncol Hematol* 2007; 61:176–85.
- Oudard S, Banu E, Beuzebec P, Voog E, Dourthe LM, Hardy-Bessard AC, Linassier C, Scotté F, Banu A, Coscas Y, Guinet F, Poupon MF, et al. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. *J Clin Oncol* 2005;23: 3343–51.
- Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. *Cancer Res* 1999;59:1152–9.
- Reubi JC, Wenger S, Schmuckli-Maurer J, Schaer JC, Gugger M. Bombesin receptor subtypes in human cancers: detection with the universal radioligand (125)I-[D-TYR(6), beta-ALA(11), PHE(13), NLE(14)] bombesin(6–14). *Clin Cancer Res* 2002;8: 1139–46.
- Sun B, Halmos G, Schally AV, Wang X, Martinez M. Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers. *Prostate* 2000;42: 295–303.
- Xiao D, Wang J, Hampton LL, Weber HC. The human gastrin-releasing peptide receptor gene structure, its tissue expression and promoter. *Gene* 2001;264: 95–103.
- Jensen RT, Battey JF, Spindel ER, Benya RV. International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. *Pharmacol Rev* 2008;60:1–42.
- Fathi Z, Corjay MH, Shapira H, Wada E, Benya R, Jensen R, Viallet J, Sausville EA, Battey JF. BRS-3: a novel bombesin receptor subtype selectively expressed in testis and lung carcinoma cells. *J Biol Chem* 1993;268:5979–84.
- Nagalla SR, Barry BJ, Creswick KC, Eden P, Taylor JT, Spindel ER. Cloning of a receptor for amphibian [Phe13]bombesin distinct from the receptor for gastrin-releasing peptide: identification of a fourth bombesin receptor subtype (BB4). *Proc Natl Acad Sci USA* 1995;92:6205–9.
- Spindel ER, Giladi E, Brehm P, Goodman RH, Segerson TP. Cloning and functional characterization of a complementary DNA encoding the murine fibroblast bombesin/gastrin-releasing peptide receptor. *Mol Endocrinol* 1990;4:1956–63.
- Wada E, Way J, Shapira H, Kusano K, Lebacqz-Verheyden AM, Coy D, Jensen R, Battery J. cDNA cloning, characterization, and brain region-specific expression of a neuromedin-B-preferring bombesin receptor. *Neuron* 1991;6:421–30.
- Ersparmer V, Ersparmer GF, Inselvini M. Some pharmacological actions of alytesin and bombesin. *J Pharm Pharmacol* 1970; 22:875–6.
- van Weerden WM, de Ridder CM, Verdaasdonk CL, Romijn JC, van der Kwast TH, Schroder FH, van Steenbrugge GJ. Development of seven new human prostate tumor xenograft models and their histopathological characterization. *Am J Pathol* 1996;149:1055–62.
- van Weerden WM, Romijn JC. Use of nude mouse xenograft models in prostate cancer research. *Prostate* 2000;43:263–71.
- de Visser M, van Weerden WM, de Ridder CM, Reneman S, Melis M, Krenning EP, de Jong M. Androgen-dependent expression of the gastrin-releasing peptide receptor in human prostate tumor xenografts. *J Nucl Med* 2007;48:88–93.
- Arnold JT, Isaacs JT. Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. *Endocrine-Related Cancer* 2002;9:61–73.
- van Steenbrugge GJ, Groen M, de Jong FH, Schroeder FH. The use of steroid-containing Silastic implants in male nude mice: plasma hormone levels and the effect of implantation on the weights of the ventral prostate and seminal vesicles. *Prostate* 1984;5:639–47.
- Bakker WH, Krenning EP, Breeman WA, Koper JW, Kooij PP, Reubi JC, Klijn JG, Visser TJ, Docter R, Lamberts SW. Receptor scintigraphy with a radioiodinated somatostatin analogue: radiolabeling, purification, biologic activity, and in vivo application in animals. *J Nucl Med* 1990;31:1501–9.
- Breeman WA, de Blois E, Krenning EP. Effects of quenchers on the radiochemical purity of ¹¹¹In-labeled peptides. *J Nucl Med* 2007;48S:73P.
- Breeman WA, De Jong M, Bernard BF, Kwekkeboom DJ, Srinivasan A, van der Pluijm ME, Hofland LJ, Visser TJ, Krenning EP. Pre-clinical evaluation of [(111)In-DTPA-Pro(1), Tyr(4)]bombesin, a new radioligand for bombesin-receptor scintigraphy. *Int J Cancer* 1999;83: 657–63.
- Breeman WA, Froberg AC, de Blois E, van Gameraen A, Melis M, de Jong M, Maina T, Nock BA, Erion JL, Macke HR, Krenning EP. Optimised labeling, preclinical and initial clinical aspects of CCK-2 receptor-targeting with 3 radiolabeled peptides. *Nucl Med Biol* 2008;35:839–49.
- Breeman WA, Hofland LJ, de Jong M, Bernard BF, Srinivasan A, Kwekkeboom DJ, Visser TJ, Krenning EP. Evaluation of radiolabelled bombesin analogues for receptor-targeted scintigraphy and radiotherapy. *Int J Cancer* 1999;81: 658–65.
- de Visser M, Bernard HF, Erion JL, Schmidt MA, Srinivasan A, Waser B, Reubi JC, Krenning EP, de Jong M. Novel (111)In-labelled bombesin analogues for molecular imaging of prostate tumours.

- Eur J Nucl Med Mol Imaging* 2007;34:1228–38.
26. De Vincentis G, Scopinaro F, Varvarigou A, Ussof W, Schillaci O, Archimandritis S, Corleto V, Longo F, Delle Fave G. Phase I trial of technetium [Leu13] bombesin as cancer seeking agent: possible scintigraphic guide for surgery? *Tumori* 2002;88: S28–S30.
 27. Panigone S, Nunn AD. Lutetium-177-labeled gastrin releasing peptide receptor binding analogs: a novel approach to radionuclide therapy. *Q J Nucl Med Mol Imaging* 2006;50:310–21.
 28. Schroeder RP, van Weerden WM, Bangma C, Krenning EP, de Jong M. Peptide receptor imaging of prostate cancer with radiolabelled bombesin analogues. *Methods (San Diego, CA)* 2009;48:200–4.
 29. Smith CJ, Volkert WA, Hoffman TJ. Gastrin releasing peptide (GRP) receptor targeted radiopharmaceuticals: a concise update. *Nucl Med Biol* 2003;30:861–8.
 30. Smith CJ, Volkert WA, Hoffman TJ. Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes. *Nucl Med Biol* 2005; 32:733–40.
 31. Van de Wiele C, Dumont F, Vanden Broecke R, Oosterlinck W, Cocquyt V, Serreyn R, Peers S, Thornback J, Slegers G, Dierckx RA. Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor- expressing malignancies: a feasibility study. *Eur J Nucl Med* 2000;27: 1694–9.
 32. Ananias HJ, de Jong IJ, Dierckx RA, van de Wiele C, Helfrich W, Elsinga PH. Nuclear imaging of prostate cancer with gastrin-releasing-peptide-receptor targeted radiopharmaceuticals. *Curr Pharm Des* 2008;14:3033–47.
 33. Davis TP, Crowell S, Taylor J, Clark DL, Coy D, Staley J, Moody TW. Metabolic stability and tumor inhibition of bombesin/ GRP receptor antagonists. *Peptides* 1992;13: 401–7.
 34. Perala-Heape M, Vihko P, Laine A, Heikkila J, Vihko R. Effects of tumour mass and circulating antigen on the biodistribution of ¹¹¹In-labelled F(ab')₂ fragments of human prostatic acid phosphatase monoclonal antibody in nude mice bearing PC-82 human prostatic tumour xenografts. *Eur J Nucl Med* 1991;18:339–45.
 35. Marques RB, van Weerden WM, Erkens-Schulze S, de Ridder CM, Bangma CH, Trapman J, Jenster G. The human PC346 xenograft and cell line panel: a model system for prostate cancer progression. *Eur Urol* 2006;49:245–57.